Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464074 · ClinicalTrials.gov registry record
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 89
- Enrollment target
NCT00464074: Completed study, sponsored by Biogen.
NCT00464074 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00464074 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2007-08-01 |
| Est. Completion | 2010-07-31 |
What the finished NCT00464074 record still lists
NCT00464074 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00464074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00464074 about?
NCT00464074 is a clinical study titled "Evaluation of Natalizumab for thE Relief of MS Associated FatiGue". This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.
What is the current status of trial NCT00464074?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2007-08-01. Estimated completion is 2010-07-31.
Who is sponsoring clinical trial NCT00464074?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI